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Abstract
Adenosine diphosphate (ADP) is a critical regulator of platelet activation, mediating its actions through two G protein-
coupled receptors, the P2Y1 and P2Y12 purinoceptors. Recently, we demonstrated that P2Y1 and P2Y12 purinoceptor
activities are rapidly and reversibly modulated in human platelets, revealing that the underlying mechanism requires
receptor internalization and subsequent trafficking as an essential part of this process. In this study we investigated the role
of the small GTP-binding protein ADP ribosylation factor 6 (ARF6) in the internalization and function of P2Y1 and P2Y12
purinoceptors in human platelets. ARF6 has been implicated in the internalization of a number of GPCRs, although its
precise molecular mechanism in this process remains unclear. In this study we show that activation of either P2Y1 or P2Y12
purinoceptors can stimulate ARF6 activity. Further blockade of ARF6 function either in cell lines or human platelets blocks
P2Y purinoceptor internalization. This blockade of receptor internalization attenuates receptor resensitization. Furthermore,
we demonstrate that Nm23-H1, a nucleoside diphosphate (NDP) kinase regulated by ARF6 which facilitates dynamin-
dependent fission of coated vesicles during endocytosis, is also required for P2Y purinoceptor internalization. These data
describe a novel function of ARF6 in the internalization of P2Y purinoceptors and demonstrate the integral importance of
this small GTPase upon platelet ADP receptor function.
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Introduction
Adenosine diphosphate (ADP) plays a key role in platelet
function. Following its secretion from platelet-dense granules ADP
amplifies the platelet responses induced by other platelet agonists
and stabilizes platelet aggregates. ADP activates two platelet G
protein-coupled receptors (GPCRs), P2Y1 and P2Y12, which
couple respectively to Gq and Gi-mediated pathways, and
synergise to induce full platelet aggregation responses to ADP
[1,2]. Interaction of ADP with P2Y1 leads to mobilization of
intracellular calcium and activation of Rho kinase, resulting in
platelet shape change and an initial wave of rapidly reversible
aggregation. In contrast, ADP stimulation of P2Y12 is associated
with adenylyl cyclase (AC) inhibition and PI3-kinase activation,
resulting in sustained aggregation in synergy with the P2Y1
receptor. Activation of both receptors is required for a full
aggregation response to ADP [3].
Recent work from our laboratory has shown that P2Y receptor
responsiveness is rapidly and reversibly modulated in human
platelets [4]. Upon prolonged exposure to agonist, the responsive-
ness of both P2Y1 and P2Y12 purinoceptors, decreases in human
platelets through different kinase-dependent mechanisms [5].
More recently, we have demonstrated that clathrin-dependent
agonist-induced internalisation, receptor dephosphorylation and
subsequent receptor recycling is required for the rapid resensitisa-
tion of P2Y receptor function in human platelets [4]. Given the
importance of these receptors in both physiological and patho-
physiological context, understanding of how P2Y receptor
function is regulated is essential for development of new
antiplatelet agents [6] both to improve existing therapies and to
provide novel therapeutic targets.
The ADP-ribosylation factor (ARF) family of small GTPases has
been implicated in the regulation of vesicle trafficking [7]. These
proteins regulate trafficking by shuttling between an active GTP-
bound form and an inactive GDP-bound form. Of the six
mammalian ARF isoforms (ARFs 1–6), ARF6 has been implicated
in the trafficking of a number of GPCRs [8,9] and has also been
shown to regulate both clathrin-dependent and independent
surface cargo binternalization [7]. In human platelets ARF6 is
present on platelet membranes and is important for platelet
function [10,11]. Unlike other small G proteins, ARF6 in its active
GTP-bound form is readily detectible in resting platelets and upon
platelet activation with collagen or convulxin rapidly converts to a
GDP-bound form [11]. This decrease in ARF6-GTP levels has
been shown to be essential for platelet aggregation, spreading on
collagen and activation of the Rho family of GTPases [11].
In the present study, we investigated the regulation of P2Y
receptor traffic and function by ARF6 in both cell lines and
importantly in human platelets. We find that blockade of ARF6
function blocks P2Y purinoceptor internalization which in turn
attenuates receptor resensitization. Furthermore, we demonstrate
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that ARF6 likely regulates receptor internalization by facilitating
dynamin-dependent internalization of these GPCRs.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), Lipofectamine
2000, fetal bovine serum and CellMaskTM Deep Red plasma
membrane stain were obtained from Invitrogen. Radiochemicals
were from Perkin Elmer Life Sciences. Complete protease
inhibitor tablets were from Roche. Anti-HA-monoclonal antibody
(HA-11), goat anti-mouse fluorescein-conjugated secondary anti-
body (1:200) was purchased from Molecular Probes. An Anti-
ARF6 mouse monoclonal antibody was obtained from SantaCruz
and a rabbit polyclonal anti-ARF1 antibody [12] was provided by
Prof. Sylvain Bourgoin (Laval University, Quebec, Canada).
SecinH3 was from Ascent Scientific. All other reagents were from
Sigma.
Preparation of Human Platelets
Human blood was drawn from healthy, drug-free volunteers
after obtaining their written informed consent on the day of the
experiment under ethical approval from the Local Research Ethics
Committee, United Bristol Healthcare Trust (Project E5736). Acid
citrate dextrose (ACD: 120 mM sodium citrate, 110 mM glucose,
80 mM citric acid, used at 1:7 vol/vol) was used as anticoagulant.
Platelet rich plasma (PRP) was prepared by centrifugation at
200 g, for 17 min and platelets were then isolated by centrifuga-
tion for 10 min at 1000 g, in the presence of 0.02 U/ml apyrase
and prostaglandin E1 (PGE1; 140 nM) for all assays other than
measurement of intracellular cyclic AMP (cAMP) where PGE1 was
omitted. The pellet was resuspended to a density of 46108
platelets/ml in a modified Tyrodes-HEPES buffer (145 mM NaCl,
2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, 5 mM glucose,
pH 7.3). To this platelet suspension 10 mM indomethacin and
0.02 U/ml apyrase were added, and a 30 min resting period was
allowed before stimulation.
Measurement of Cytosolic Free Calcium ([Ca2+]i) in
Platelets
Measurement of cytosolic calcium was performed as previously
described [4,5]. Briefly, 3 mM Fura-2-AM was added to platelet
rich plasma, and incubated at 37uC for 45 min in the presence of
10 mM indomethacin. Platelets were centrifuged and re-suspended
in modified Tyrodes. ADP (1 nM 210 mM)-induced calcium
responses were subsequently measured at 37uC using a Hitachi F-
4500 spectrofluorimeter with fluorescence excitation made at
340 nm and 380 nm and emission at 510 nm. The ratio of the
emissions (F1/F2) at those wavelengths is directly correlated to the
amount of intracellular calcium. Raw data are expressed as F1/F2
whilst collated data is expressed as % Peak calcium response (%
10 mM ADP alone). To induce receptor desensitisation, a
desensitising concentration of ADP (10 mM) was added to platelets
for 5 min. Subsequently a stimulating concentration of ADP
(10 mM) was added, and the response monitored. Since the ADP
response in platelets is attenuated following multiple spin wash
steps, desensitising ADP was then removed by the addition of
0.2 unit/ml apyrase (10 min), rather than a wash and spin-step, to
promote receptor resensitization. Following apyrase treatment a
stimulating concentration of ADP (10 mM) was again added, and
the response measured. In all experiments, non-desensitised
controls were performed where no desensitising ADP was added.
Similarly, the responses of (non-desensitised) platelets to ADP were
determined in the presence and absence of apyrase in order to
verify that apyrase did not affect stimulations.
Measurement of cAMP Levels in Platelets
P2Y12 purinoceptor activity was assessed in human platelets as
previously described [5]. Briefly, platelets were stimulated in the
presence of the phosphodiesterase inhibitor IBMX (100 mM) 6
forskolin (1 mM) in the absence or presence of ADP (10 mM) for
5 min at 37uC. Cyclic AMP accumulation was terminated by
addition of ice cold 100% trichloroacetic acid (TCA) and samples
were left to lyse on ice for 1–2 hrs. The resulting samples were
spun at 4000 g for 5 min and the cAMP-containing supernatant
neutralized with 1 M NaOH and TE buffer (50 mM Tris-HCl,
4 mM EDTA, pH 7.4). Cyclic AMP levels were subsequently
determined in each sample using a binding assay as previously
described [5]. Receptor desensitization was performed as previ-
ously described [5]. Briefly, in order to induce receptor
desensitization platelets were stimulated with ADP (10 mM;
5 min). In order to induce receptor resensitization apyrase
(0.2 unit/ml; 10 min) was subsequently added to remove desen-
sitizing ADP from platelets. As previously described 1 mM EGTA
was added 1 min prior to cAMP accumulation experiments to
negate calcium dependent-apyrase activity [5]. cAMP accumula-
tion assays were performed on non-desensitised control, desensi-
tised or resensitized platelets. Data are presented as % inhibition of
forskolin-stimulated adenylyl cyclase.
Radioligand Binding in Human Platelets
Platelets were pre-treated with SecinH3 (15 mM; 15 min) or
vehicle alone. To induce receptor internalization platelets were
subsequently stimulated with ADP (10 mM, 5 min) or vehicle
alone. To induce subsequent receptor recycling ADP was removed
with apyrase (0.2 unit/ml; 10 min). P2Y1 and P2Y12 surface
receptor expression was subsequently determined by ligand
binding in fixed platelets as previously described [4].
Measurement of Platelet Aggregation
Washed platelets were pre-treated with SecinH3 (15 mM;
15 min) or vehicle alone. Platelets were stimulated with ADP
(10 mM) in the presence of 1 mg/mL fibrinogen and platelet
aggregation measured in a Born optical aggregometer (Chrono-
log, Havertown, PA, USA) at 37uC under continuous stirring at
800 g.
Cell Culture
1321N1 Human astrocytoma cells stably expressing either
hemagglutinin (HA)-Tagged human P2Y1 or P2Y12 receptor were
Generated as previously described [5]. cells were maintained in
dmem supplemented with 10% fetal bovine serum, 100 units ml21
penicillin G, 100 mG ml21 streptomycin sulfate and 400 mG/ML
geneticin at 37uC supplemented with in a humidified atmosphere
of 95% air, 5% CO2.
ARF6 Activation Assay in 1321N1 Cells and Human
Platelets
ARF6 activation was assessed by using the GST pulldown assay
as described previously [13,14]. Briefly, 1321N1 human astrocy-
toma cells stably expressing either HA-tagged human P2Y1 or
P2Y12 receptor were grown in 10-cm plates were washed twice
with ice-cold PBS and harvested using 0.5 ml of ice-cold lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS and 10 mM MgCl2)
with 1% protease inhibitors mix (Sigma). The cell lysates were
Regulation of Platelet ADP Receptor Function
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incubated with glutathione-Sepharose beads coupled to 50 mg of
purified GST-GGA3 VHS-GAT fusion protein at 4uC for
2 hours. The beads were washed three times with the wash buffer
(50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 150 mM NaCl and
1% Triton X-100). The lysates that not incubated with the beads
were used as an input controls. ARF6-GTP or ARF1-GTP bound
to the beads and total ARF6 and ARF1 in the inputs were
determined by immunoblotting using either an anti-ARF6 mouse
monoclonal antibody or an anti-ARF1 rabbit polyclonal antibody
[15]. Immunoblots were scanned and the GTP-bound ARF6 or
ARF1 precipitated with GST-GGA3 VHS-GAT beads was
normalised to total ARF6 or ARF1 levels in the lysates. GST-
GGA3 VHS-GAT fusion protein was expressed in BL21(DE3)
strain of E. coli and coupled to glutathione-beads as described [16].
Internalization and Immunofluorescence Microscopy of
HA-P2Y1 and HA-P2Y12 in 1321N1cells
HA-tagged surface receptor loss was assessed by ELISA as
described previously [17]. Briefly, cells plated at a density of
around 66105 cells per 60 mm dish were transiently transfected
with pcDNA3 containing dominant-negative mutant (DNM) of
ARF6 (ARF6 T27N; ARF6-DNM), or ARF1 (ARF1 T31N;
ARF1-DNM) or Nm23-H1 (H118C Nm23-H1, a kinase defective)
[9,18]. Twenty-four hours post-transfection, cells were split into
24-well tissue culture dishes coated with 0.1 mg ml21 poly-L-
lysine. Twenty-four hours later, cells were incubated with DMEM
containing apyrase (0.1 unit/ml; 1 h) and SecinH3 (15 mM;
30 min) or vehicle alone. In parallel experiments, cells were
incubated for 30 minutes with penetratin-coupled-myristoylated
(Myr) inhibitory ARF peptides (myr-ARF1-peptide and myr
ARF6-peptide) or penetratin vehicle alone (Vehicle). Cells were
then washed and challenged with DMEM containing ADP
(10 mM) for 0–15 min at 37uC. In order to induce receptor
recycling apyrase was added (0.2 unit/ml) to remove ADP.
Changes in surface receptor expression were subsequently
determined by an immunosorbent assay (ELISA) taking advantage
of the HA-epitope tag [17], and expressed as either % surface
receptor or % loss of surface receptor with the background signal
from pcDNA3-transfected controls subtracted from all receptor-
transfected values.
Cellular distribution of HA-tagged receptor in 1321N1 cells was
assessed by immunofluorescence microscopy [17]. Briefly cells
were grown on poly-L-lysine coated coverslips in 6 well plates.
Twenty-four hours later, receptor distribution was assessed using a
primary anti-HA-monoclonal antibody (HA-11; 1:200) and goat
anti-mouse fluorescein-conjugated secondary antibody (1:200).
Cell plasma membrane was stained using CellMaskTM Deep Red
plasma membrane stain. Coverslips were mounted using Slow-
Fade mounting medium and examined by microscopy on an
upright Leica TCS-NT confocal laser scanning microscope
attached to a Leica DM IRBE epifluorescence microscope with
phase-contrast and a Plan-Apo 4061.40 NA oil immersion
objective. All images were collected on Leica TCS-NT software
for 2D and 3D image analysis and processed using Adobe
Photoshop 6.0.
Figure 1. Over-expression of ARF6-DNM attenuates agonist-internalization of both the P2Y1 and P2Y12 purinoceptor. 1321N1 human
astrocytoma cells stably expressing either HA-tagged P2Y1 and P2Y12 purinoceptor were transiently transfected with either constitutively inactive
mutant forms of ARF6 (ARF6 T27N; ARF6-DNM) or ARF1 (ARF1 T31N; ARF1-DNM). Over-expression of DNM forms of ARF1 or ARF6 was confirmed by
Western Blotting which showed a 4–5 fold increase over endogenous levels of ARF proteins (data not shown). Cells were subsequently treated with
ADP (10 mM; 0–30 min) and surface receptor loss assessed by ELISA (Fig. 1A and Fig. 1B) or receptor internalization visualized by confocal
immunofluorescent microscopy (Fig. 1C). In Figure 1A and 1B the data represent means 6 SEM of five independent experiments. *p,0.05 compared
with respective vector alone controls (Mann–Whitney U-test). In Figure 1C receptor cell surface expression was assessed by examining co-localization
with a plasma membrane marker (CellMaskTM Plasma Membrane Stain).
doi:10.1371/journal.pone.0043532.g001
Figure 2. P2Y1 and P2Y12 purinoceptor stimulation increases
ARF6-GTP levels in 1321N1 cells. 1321N1 human astrocytoma cells
stably expressing either HA-tagged P2Y1 or P2Y12 purinoceptor were
treated with ADP (10 mM; 5 min) and analysed the endogenous ARF-
GTP levels by using GST-GGA3 VHS-GAT pull down assay. Total ARF6 (A)
or ARF1 (B) expression in the cell lysates and ARF6-GTP (A) or ARF1-GTP
(B) precipitated with GST-GGA3 VHS-GAT beads were detected by
immunoblotting using an anti-ARF6 mouse monoclonal and an anti-
ARF1 rabbit polyclonal antibodies. The relative intensity of each ARF6-
GTP or ARF1-GTP band was normalised to total ARF6 or ARF1 measured
by densitometry. Values are mean 6 SEM from five separate
experiments. *p,0.05 compared with no ADP treatment alone control
(Mann–Whitney U-test).
doi:10.1371/journal.pone.0043532.g002
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Figure 3. Inhibition of ARF6 activity in 1321N1 cells attenuates internalization of both the P2Y1 and P2Y12 purinoceptor. 1321N1
human astrocytoma cells stably expressing either HA-tagged P2Y1 and P2Y12 purinoceptor were incubated with either (A) penetratin-coupled-
myristoylated (Myr) inhibitory ARF peptides (myr-ARF1-peptide and myr ARF6-peptide) or penetratin vehicle alone (Vehicle) or (B and C) SecinH3
(15 mM) or vehicle control for 30 minutes prior to study. In (A) and (B) cells were subsequently treated with ADP (10 mM; 30 min) and surface receptor
loss assessed by ELISA. The data represent means 6 SEM of five independent experiments. *p,0.05 compared with respective control (Mann–
Whitney U-test). In (C) inhibition of P2Y-stimulated ARF6-GTP levels by SecinH3 treatment was assessed. Cells expressing either HA-tagged P2Y1 and
P2Y12 purinoceptor were pretreated with SecinH3 (15 mM) or vehicle control for 30 minutes prior to study. Total ARF6 expression in the cell lysates
and ARF6-GTP precipitated with GST-GGA3 VHS-GAT beads were detected by immunoblotting using an anti-ARF6 mouse monoclonal. The relative
intensity of each ARF6-GTP band was normalised to total ARF6 and measured by densitometry. Values are mean 6 SEM from three separate
experiments. *p,0.05 compared with no ADP treatment alone control (Mann–Whitney U-test).
doi:10.1371/journal.pone.0043532.g003
Figure 4. P2Y1 and P2Y12 purinoceptor internalization is ARF6-dependent in human platelets. Platelets were incubated with either
penetratin-coupled-myristoylated (Myr) inhibitory ARF6 peptide or penetratin vehicle alone or SecinH3 (15 mM) for 30 minutes prior to study.
Platelets were subsequently exposed to ADP (10 mM; 5 min) to promote receptor internalization. Surface receptor levels were subsequently
measured in fixed platelets using [3H]-2MeSADP (100 nM) in the presence of either the P2Y1 receptor antagonist A3P5P (1 mm) or the P2Y12 receptor
antagonist AR-C69931MX (1 mm). In (A) data are expressed as [3H]-2MeSADP (DPM) and in (B) data are expressed as percent internalization of surface
receptor. Values are mean 6 SEM from four separate experiments. In (B) *p,0.05 compared with respective vehicle control (Mann–Whitney U-test).
doi:10.1371/journal.pone.0043532.g004
Regulation of Platelet ADP Receptor Function
PLOS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e43532
Regulation of Platelet ADP Receptor Function
PLOS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e43532
Experimental Design and Statistics
Data were analysed by the iterative fitting program GraphPAD
Prism (GraphPAD Software). Log concentration-effect curves
were fitted to logistic expressions for single-site analysis, whilst t0.5
values for agonist-induced internalization were obtained by fitting
data to single exponential curves. Where appropriate statistical
significance was assessed by Mann-Whitney-U test or by two-way
ANOVA.
Results
In order to study the role of ARF6 in either P2Y1 or P2Y12
purinoceptor function and circumvent the inherent methodolog-
ical problems that this presents in platelets, we initially examined
these receptors in a cell line system. In these studies we used
1321N1 human astrocytoma cells stably expressing N-terminal
HA-epitope tagged versions of either receptor. Using these cells we
are able to quantify receptor signaling and agonist-induced surface
receptor loss by ELISA and immunofluorescence microscopy as
previously described [17]. We initially sought to determine the
effects of ARF6 on agonist-induced P2Y1 and P2Y12 purinoceptor
internalization. Cells were transiently transfected with a constitu-
tively inactive mutant form of ARF6 (ARF6 T27N; ARF6-DNM),
previously shown to inhibit ARF6-dependent internalization of the
b2-adrenoceptor [9]. Expression of this construct significantly
attenuated both P2Y1 (Fig. 1A) and P2Y12 (Fig. 1B) purinoceptor
as assessed by ELISA (Fig. 1A and 1B). Expression of a
constitutively inactive form of ARF1 (ARF1 T31N; ARF1-
DNM) had no effect on either P2Y1 (Fig. 1A) or P2Y12 (Fig. 1B)
purinoceptor internalization. Western blotting confirmed that
both ARF1-DNM and ARF6-DNM are expressed after transient
transfection (70–90% cells transfected at 4–5 fold over endogenous
ARF6 levels; data not shown). Confocal imaging of P2Y1 and
P2Y12 purinoceptor localization showed that whereas in control
cells or those transfected with ARF1-DNM, agonist treatment led
to the marked accumulation of receptor in endosome-like
structures as previously described in the cell cytoplasm, this
accumulation was greatly reduced when ARF6-DNM was
cotransfected into the cells. Comparison with a plasma membrane
dye suggested that both the P2Y1 and P2Y12 purinoceptor was
retained at the cell surface following ARF6-DNM expression.
Given these findings we next sought to determine if activation of
either of these receptors may increase ARF6 activity (Fig. 2).
Active ARF-GTP binds specifically to VHS-GAT domain of
GGA3, a downstream effector. Therefore, the VHS-GAT of
GGA3 can be used as a probe to specifically isolate the active
forms of ARF1 and ARF6. We therefore examined ARF6
activation using a GST–GGA3 pull down assay as previously
described [13,14,16]. P2Y1 or P2Y12 purinoceptor expressing cells
were transiently transfected with HA-tagged forms of ARF1 or
ARF6. Importantly ADP-treatment of these cells specifically
increased ARF6-GTP levels in these cells whilst ARF1-GTP levels
were unaffected.
We subsequently used two alternative strategies to inhibit
endogenous ARF6 activity in these cells, using either a peptide or
chemical inhibitor approach (Fig. 3). Given the anuclear nature of
platelets we intended to validate these approaches in cell line
systems prior to their translation into human platelets. For the
peptide strategy two Myristoylated (Myr) inhibitory ARF peptides
(myr-ARF1-peptide and myr ARF6-peptide) that contain the N-
terminal residues [19–20] of these proteins were utilized that are
effective in inhibiting the functional activity of ARFs [20]. In order
to facilitate entry of these peptides into cells we coupled them to
penetratin [21,22] which has been used successfully to internalize
covalently attached peptides and oligonucleotides and to convey
them to the cytoplasm and nucleus of many cell types. Cells were
therefore incubated with these penetratin-conjugated peptides
(myr-ARF1- or myr-ARF6-peptide) or penetratin alone (vehicle)
and agonist-induced internalization examined (Fig. 3A). Impor-
tantly as with our DNM studies treatment with only the myr-
ARF6-peptide inhibited ADP-stimulated receptor internalization
as assessed by ELISA.
For the chemical approach we used SecinH3, a Sec7-specific
Guanine nucleotide exchange factor (GEF) inhibitor that displays
selectivity for GEFs of the cytohesin family [23,24]. It is well
established that the binding of the ARF6-GEF cytohesin 2 (also
known as ARNO) promotes the exchange of GDP for GTP
promoting ARF6 activation. Therefore inhibition of ARNO with
SecinH3 will inhibit ARF6 activation. We have recently demon-
strated that SecinH3 inhibits the agonist-induced internalization of
Luteinizing Hormone Chorionic Gonadotropin (LHCG) receptor
[18]. Treatment with SecinH3 also blocked agonist-stimulated
P2Y1 or P2Y12 purinoceptor internalization (Fig. 3B). Importantly
treatment of 1321N1 cells with SecinH3 inhibited ADP-stimulated
ARF6-GTP-levels in either P2Y1 or P2Y12 purinoceptor express-
ing cells (Fig. 3C). Given these results with the Myr-ARF6-peptide
and SecinH3 in cell lines we next examined the ability of these
agents to inhibit P2Y purinoceptor internalization in human
platelets.
We have previously used a ligand binding approach to examine
P2Y1 or P2Y12 purinoceptor internalization and recycling in
human platelets [17]. We examined surface expression of ADP
receptors on platelets by ligand binding using [3H]-2MeSADP
(100 nM) in the presence of A3P5P (1 mM) or AR-C69931MX
(1 mM) to distinguish either the P2Y1 or P2Y12 surface binding
sites as previously reported [4,17]. Importantly treatment with
Myr-ARF6 peptide or SecinH3 did not significantly change
control/basal levels or either P2Y1 or P2Y12 purinoceptor surface
expression (clear bars Fig. 4A). As in our previous studies,
following pretreatment with ADP (10 mM; 5 min), its subsequent
removal with apyrase (0.2 unit mL21; 3 min) and platelet fixation,
there was a clear reduction in [3H]-2MeSADP binding to both
P2Y1 and P2Y12 compared with apyrase-alone treated controls.
Data shown are summarized in Figure 4B. As expected, if we
lengthened the period of apyrase exposure to 10 minutes (ADP/
apyrase), we found that both the P2Y1 and P2Y12 surface receptor
Figure 5. P2Y purinoceptor stimulation increases ARF6-GTP levels in human platelets. (A and B) Human platelets were treated with ADP
(10 mM; 0–5 min) and endogenous ARF-GTP levels assessed by using GST-GGA3 VHS-GAT pull down assay. Total ARF6 (A) or ARF1 (B) expression in
platelet cell lysates and ARF6-GTP (A) or ARF1-GTP (B) precipitated with GST-GGA3 VHS-GAT beads were detected by immunoblotting using an anti-
ARF6 mouse monoclonal and an anti-ARF1 rabbit polyclonal antibodies. The relative intensity of each ARF6-GTP or ARF1-GTP band was normalised to
total ARF6 or ARF1 measured by densitometry (A and B). Values are mean 6 SEM from three separate experiments. *p,0.05 compared with no ADP
treatment alone control (Mann–Whitney U-test). (C) Human platelets were treated with thrombin (0.3 unit/ml) and collagen-related peptide (CRP;
5 mg/ml) for 0–5 mins and and endogenous ARF-GTP levels assessed. The data are representative of three independent experiments (D) Platelets
were incubated with SecinH3 (15 mM) or vehicle alone for 30 minutes. Platelets were then treated with ADP (10 mM; 0–5 min) and endogenous ARF6-
GTP levels assessed. The data represent mean 6 SEM of three independent experiments. *p,0.05 compared with no ADP treatment alone control
(Mann–Whitney U-test).
doi:10.1371/journal.pone.0043532.g005
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Figure 6. ARF6-dependent P2Y1 and P2Y12 purinoceptor internalization is required for effective receptor regulation in human
platelets. Platelets were incubated with SecinH3 (15 mM) or vehicle alone for 30 minutes and P2Y1 (A and B) or P2Y12 (C and D) purinoceptor
activity subsequently assessed. In (A) and (B) P2Y1 purinoceptor stimulated calcium signalling was assessed. (A) Full dose response curve of ADP
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levels returned to control levels (Fig. 4A). We next examined if
receptor internalization was impaired in platelets treated with
Myr-ARF6 peptide or SecinH3 (Fig. 4A and 4B). Importantly
pretreatment with either Myr-ARF6-peptide or SecinH3 inhibited
ADP stimulated receptor internalization (Fig. 4A and 4B).
We next sort to determine if either P2Y1 or P2Y12 purinoceptor
activation in human platelets promoted ARF6 activation. We
again made use of the ability of active ARF-GTP to bind
specifically to VHS-GAT domain of GGA3, a downstream
effector as previously described [13,14,16]. Importantly activation
of human platelets with ADP (10 mM) promoted a transient but
robust increase in ARF6-GTP levels (Fig. 5A) whilst ARF1-GTP
levels (Fig. 5B) were unaffected. Given this difference to other
studies where ADP treatment was shown to have no effect on
ARF6-GTP levels [10,11], we further examined if other platelet
agonists could increase ARF6-GTP levels. Interestingly we found
that aswell as ADP addition of both thrombin (0.3 unit/ml) and
collagen-related peptide (CRP; 5 mg/ml) could promote a rapid
and transient increase in ARF6-GTP levels (Fig. 5C). Importantly
pretreatment of platelets with SecinH3 attenuated ADP-depen-
dent increases in ARF6-GTP levels (Fig. 5D) indicating that in
human platelets SecinH3 was effectively inhibiting ARF6 activa-
tion.
Therefore we next examined if treatment with SecinH3
attenuated receptor P2Y1 or P2Y12 purinoceptor signaling
desensitization or resensitization. P2Y1–stimulated rises in intra-
cellular calcium and P2Y12-inhibition of forskolin-stimulated
adenylyl cyclase were measured as is standard in our laboratory
[5]. SecinH3 pretreatment did not significantly attenuate the acute
ADP-dependent signaling of either the P2Y1 or P2Y12 purino-
ceptor (Fig. 6A and 6C). In order to examine receptor
desensitization and resensitization platelets were pretreated with
ADP to desensitize receptor responses, and then allowed to
recover in the presence of apyrase added to remove desensitizing
ADP to examine resensitization of responses as previously
described [4]. As expected and previously reported [4], pretreat-
ment with agonist (ADP; 10 mM; 5 min) decreased subsequent
ADP-stimulated P2Y1 (Fig. 6B) and P2Y12 (Fig. 6D) purinoceptor
responses whilst prolonged addition of apyrase (0.2 units/ml;
30 mins) led to a resensitization of both receptor responses.
Pretreatment with SecinH3 did not significantly affect receptor
desensitization but did completely abolish receptor resensitization
(Figure 6B and 6D). Therefore ARF6-dependent internalization of
the P2Y1 or P2Y12 purinoceptor is required for effective
resensitization of these receptors. We subsequently tested if
ARF6 also played any role in regulating ADP-dependent platelet
aggregation. Importantly we found that pretreatment with
SecinH3 (100 mM; 15 mins) did significantly attenuate ADP
(10 mM)-dependent platelet aggregation (sample trace Figure 6E
with averaged data Figure 6F).
Given these results and previous studies from our group we next
sought to examine how ARF6 may regulate P2Y1 or P2Y12
purinoceptor internalization. Both of these GPCRs internalize in a
clathrin- and dynamin-dependent manner in human platelets.
ARF6 has been shown to regulate the activity of dynamin by an
interaction with the Nucleoside diphosphate kinase Nm23-H1
[25,26]. ARF6-interacts with and recruits Nm23-H1 to the cell
membrane where it provides a local source of GTP for the
GTPase dynamin. Unfortunately given the lack of an applicable
approach (either chemical or peptide) to examine the function of
Nm23-H1 in human platelets we examined the ability of this
protein to regulate P2Y1 or P2Y12 purinoceptor internalization in
1321N1 cells. In these studies we used a DNM of Nm23-H1
(H118C Nm23-H1; [26]) that we have recently shown to inhibit
the ARF6-dependent internalization of another GPCR, the
LHCG receptor [18]. Expression of this DNM did indeed
significantly attenuate both P2Y1 and P2Y12 purinoceptor
internalization (Figure 7A).
ARF6 activation has been shown to increase GPCR association
to components of clathrin-coated pits (CCPs) [27]. Therefore we
examined if this was also the case for the P2Y1 or P2Y12
purinoceptor (Fig. 7B). We have previously shown that these
receptors associate with a-adaptin, a core component in CCPs
following ADP stimulation [17]. We therefore examined if
receptor/a-adaptin association was reduced following pre-treat-
ment with SecinH3. As expected ADP stimulation (10 mM; 5 min)
increased P2Y1 and P2Y12 purinoceptor/a-adaptin association
(Fig. 7B). Importantly SecinH3 pretreatment significantly attenu-
ated this association. Therefore we postulate that ARF6 promotes
clathrin-dependent internalization of these receptors by increasing
receptor association with CCP components and through the
recruitment of Nm23-H1 (Fig. 7C).
Discussion
In the present study, we describe the novel finding that the small
GTPase ARF6 regulates the clathrin-dependent internalisation of
both P2Y1 and P2Y12 purinoceptors and is required for the
maintenance of receptor function in human platelets. The
activation of P2Y1 and P2Y12 purinoceptors by ADP is critical
for normal platelet function, performing a pivotal role in the
formation of stable platelet aggregates with continuous ADP
signaling facilitating thrombus stability [28,29]. Previous studies
from our laboratory have shown that the responses of P2Y1 and
P2Y12 are able to rapidly respond to changes in circulating ADP
levels and that the sensitivity of these receptors to agonist is
(1 nM-10 mM)-stimulated of P2Y1 purinoceptor activity. (B) P2Y1 purinoceptor desensitization was assessed by comparing receptor activity (ADP;
10 mM) before (untreat) and after pretreatment with ADP (10 mM; 5 min; desens). Subsequent receptor resensitization (resens) was assessed following
removal of desensitizing ADP with apyrase (0.2 unit mL21; 10 min). Data are expressed as the percent peak calcium response obtained from the
initial control ADP (10 mM) response. The data represent mean 6 SEM of four independent experiments. p,0.05 compared with untreated control
(Mann–Whitney U-test). #p,0.05 compared with resensitized control in the absence of SecinH3 treatment (Mann–Whitney U-test). In (C and D)
P2Y12 purinoceptor stimulated inhibition of forskolin (1 mm; 5 min)-stimulated adenylyl cyclase activity was assessed. (C) Full dose response curve of
ADP (0.01 nM-10 mM)-stimulated P2Y12 purinoceptor activity. (D) P2Y12 purinoceptor desensitization was assessed by comparing receptor activity
(ADP; 10 mM) before (untreat) and after pretreatment with ADP (10 mM; 5 min; desens). Subsequent receptor resensitization (resens) was assessed
following removal of desensitizing ADP with apyrase (0.2 unit mL21; 10 min). Data are expressed as the percentage inhibition of forskolin-stimulated
adenylyl cyclase. The data represent mean 6 SEM of four independent experiments. *p,0.05 compared with untreated control (Mann–Whitney U-
test). #p,0.05 compared with resensitized control in the absence of SecinH3 treatment (Mann–Whitney U-test). In (E and F) Washed platelets were
pretreated with SecinH3 (100 mM; 15 min) in the presence of 1 mg/ml fibrinogen. Platelets were subsequently stimulated with ADP (10 mM), and the
resultant aggregation response was monitored by optical aggregometry. (E) Shows a representative trace from at least three experiments with ADP
added at time point 0 and aggregation expressed as optical density (O.D.) In (F) data are expressed as maximum aggregation (O.D.) following
300 seconds ADP stimulation. The data represent mean 6 SEM of three independent experiments. *p,0.05 compared with untreated control
(Mann–Whitney U-test).
doi:10.1371/journal.pone.0043532.g006
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continuously regulated in order to avoid inappropriate thrombosis.
Receptor desensitization and then subsequent resensitization
represent key mechanisms by which the delicate balance between
rest and activation of platelets in the circulation is maintained.
Upon prolonged exposure to ADP, the responsiveness of both
P2Y1 and P2Y12 purinoceptors desensitize via different protein
kinase C (PKC)- and GRK-dependent mechanisms, respectively
[5], and subsequently enter distinct subpopulations of CCPs prior
to internalisation in human platelets [17]. More recently, we have
demonstrated that following clathrin-dependent agonist-induced
internalisation, receptor dephosphorylation and subsequent recep-
tor recycling is required for the rapid resensitisation of P2Y
purinoceptor function [4].
Although we have previously demonstrated that P2Y purino-
ceptors internalize in human platelets in a dynamin-dependent
manner little is still known about the molecular mechanisms
underlying this process in human platelets. The small GTPase
ARF6, which is endogenously expressed in human platelets [10]
regulates both clathrin-dependent and independent endocytic
pathways of multiple membrane cargo including many GPCRs
[8,9]. Our initial studies in cell lines demonstrated that blockade of
ARF6 activity, either by the use of ARF6-DNM, Myr-ARF6-
peptide or ARF6-GEF chemical inhibitor SecinH3, attenuated
P2Y1 and P2Y12 purinoceptor internalization. Further in our cell
line studies we demonstrated that activation of these receptors
promoted ARF6 activation. Therefore by their activation these
receptors are able to increase ARF6 activity and promote their
own internalization. Further detailed study will be required to
determine how receptor stimulation increases ARF6 activity
although it should be noted that the P2Y12 purinoceptor associates
with arrestins upon receptor activation [17]. Arrestins have been
shown to associate with ARF6 and potentiate its activation by the
ARF6-GEF ARNO, which has also been found in complex with
arrestins [30].
Classically, ARF proteins are known as molecular switches, by
cycling between active GTP-bound and inactive GDP-bound
conformations, that coordinate several cellular events such as
vesicle trafficking, actin remodeling, and modification of mem-
brane lipid content. For example, at the Golgi, the activation of
ARF1 can promote the recruitment of COP I, COP II, and
clathrin; components necessary for the formation of trafficking
vesicles [31,32,33]. At the plasma membrane, ARF6 is able to
promote clathrin/AP-2 recruitment to synaptic membranes by
activating the phosphatidylinositol phosphate kinase type 1c [34].
The ability of ARF6 to regulate receptor internalization has now
been demonstrated for a number of GPCRs including the b2-
adrenergic (b2AR) [8] and TP thromboxane receptors [35].
Indeed, depletion of ARF6 by siRNA results in a marked
inhibition of receptor internalization utilizing different endocytic
pathways demonstrating the importance of this small GTP-
binding protein in regulating the endocytic process [8]. Interest-
ingly for the angiotensin II AT1a receptor ARF6 coordinates the
recruitment of AP-2 and clathrin, integral proteins found in CCPs
to activated receptors during the endocytic process promoting
receptor internalization [27]. Both the P2Y1 and P2Y12 purino-
ceptor internalize in a clathrin-dependent manner. Our studies
show that blockade of ARF6 activity attenuates P2Y1 and P2Y12
purinoceptor association with a-adaptin, a core component of
CCPs.
We also find that Nm23-H1, an NDP-kinase, regulates P2Y
purinoceptor internalization. Nm23-H1 is encoded by the
Drosophila melanogaster abnormal wing dics (awd) gene and belongs to
a family of structurally conserved NDP-kinase that generate
nucleoside triphosphates from respective diphosphates [25,26].
Nm23-H1 has been shown to provide a source of GTP during
dynamin-dependent vesicle fission in nerve terminals [26] and
regulate membrane cargo internalization [36] including that of
another GPCR the LHCG receptor [18] whilst Nm23-H2
regulates the internalization of GPCRs including the TP
thromboxane receptor [37]. ARF6 has been shown to interact
with and recruit Nm23-H1 to the cell membrane where it provides
a local source of GTP for the GTPase dynamin [26]. We therefore
postulate that P2Y purinoceptor activation stimulates ARF6 which
in turn promotes clathrin-dependent receptor internalization via
an Nm23-H1-dependent stimulation of dynamin activity.
Importantly in our studies we have translated our findings with
over-expressed receptors in cell lines into human platelets. Both
the Myr-ARF6-peptide and SecinH3 block P2Y1 and P2Y12
purinoceptors internalization. Importantly although ARF6 block-
ade does not attenuate acute P2Y purinoceptor signalling it does
block receptor resensitization. Importantly we were able to show
that ADP-stimulation promoted transient but robust ARF6
activation in platelets. This is different from previous studies
where ADP treatment was shown to have no effect on ARF6-GTP
levels [10,11]. There a number of subtle but important differences
between these studies and our findings. Previously the full time-
course of ADP-dependent increases in ARF6-GTP levels were not
investigated whilst platelets were incubated for 2–5 min at 37uC
before ADP addition. Importantly, unlike the previous studies,
during platelet preparation we incubate our platelets in the
presence of the ADP scavenger apyrase (0.02 unit/ml) in order to
retain platelet P2Y responsiveness. We find that these receptors
are extremely sensitive to ADP secreted during platelet prepara-
tion which can desensitize their function [4,5]. Interestingly we
find that without the addition of apyrase we lose platelet ADP-
dependent ARF6 activation and even see a transient increase in
ARF6 activity on incubating platelets at 37uC which is blocked by
the addition of P2Y1 and P2Y12 receptor antagonists (data not
shown). Interestingly we also find a transient increase in both
thrombin-activated PAR and collagen-activated GPVI receptors
in our studies whereas ARF6-GTP levels have been reported to
decrease [10,11]. The consequences of these changes in ARF6-
GTP levels upon P2Y purinoceptor internalization are unclear
and require further detailed investigation, although in our study
Figure 7. ARF6 regulates aspects of clathrin- and dynamin-dependent P2Y1 or P2Y12 purinoceptor receptor internalization. (A)
1321N1 human astrocytoma cells stably expressing either HA-tagged P2Y1 and P2Y12 purinoceptor were transfected with a dominant negative
mutant of the Nucleoside diphosphate kinase Nm23-H1 (H118C Nm23-H1). Cells were subsequently treated with ADP (10 mM; 30 min) and surface
receptor loss assessed by ELISA. The data represent mean 6 SEM of four independent experiments. *p,0.05 compared with pcDNA3 vector control
(Mann–Whitney U-test). (B) 1321N1 human astrocytoma cells stably expressing either HA-tagged P2Y1 and P2Y12 purinoceptor were treated with
SecinH3 (15 mM) for 30 minutes. Cells were subsequently stimulated with ADP (10 mm; 5 min) at 37uC. Reactions were stopped by addition of ice-cold
lysis buffer and receptor was immunoprecipitated from cell lysates using an anti-HA antibody (HA-11) and association with endogenous a-adaptin
assessed by immunoblotting. Whole-cell lysates (WCL) lanes are included as positive controls for detection by anti-a-adaptin antibodies as are lanes
showing equal levels of receptor immunoprecipitation. (C) Model of ARF6-dependent internalization of P2Y1 and P2Y12 purinoceptor. Activation of
the P2Y1 and P2Y12 purinoceptor increases ARF6 activation. ARF6-GTP in turn stimulates Nm23-H1 which in turn promotes dynamin-dependent
internalization of the P2Y1 and P2Y12 purinoceptors.
doi:10.1371/journal.pone.0043532.g007
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reduced ARF6 function attenuates the internalization and
resensitization of these receptors Importantly we also find that
inhibition of ARF6 with SecinH3 attenuates ADP-dependent
platelet aggregation. We speculate that this attenuation of ADP-
dependent platelet aggregation maybe as consequence of reduced
P2Y receptor internalization and resensitization although the true
physiological consequence of P2Y receptor traffic upon platelet
function is still to be determined.
In conclusion this work expands our understanding of the
molecular regulators of platelet purinoceptor function. Given the
physiological and pathophysiological importance of platelet P2Y
purinoceptor function, this study demonstrates the integral
importance of the small GTPase ARF6 upon ADP signalling in
human platelets. Further study is now required to determine the
functional importance of ARF6 upon ADP-dependent thrombus
generation and stabilization.
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